CELLINK, a bioconvergence startup, agreed to acquire Nanoscribe, a German company focusing on development of high-precision 3D printers, for €50m ($61m). "With this strategic acquisition of Nanoscribe, we will further strengthen our market leading position within the 3D bioprinting segment. With Nanoscribe’s state of the art 2PP technology, we will complement our product portfolio and offer a wider range of products to our amazing customers. We are combining our strong, purpose driven growth agenda with trailblazing bioconverging technologies for the sake of improving health all around the world," Erik Gatenholm, CELLINK CEO.